Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wearable Devices Ltd. (WLDS) SEC filings page on Stock Titan aggregates the company’s public reports as a foreign private issuer, giving investors structured access to its regulatory disclosures. Wearable Devices files primarily on Form 6-K under the Securities Exchange Act of 1934, and these reports often attach press releases or transaction documents that explain key corporate and financing events.
Recent 6-K filings describe registered direct offerings of ordinary shares and pre-funded warrants, concurrent private placements of ordinary warrants, and an at-the-market sales agreement for ordinary shares. These filings outline terms such as offering structures, use of registration statements on Form F-3, warrant exercise conditions, lock-up provisions and commission arrangements with placement agents or sales agents. Other 6-Ks cover matters like annual and special general meetings, amendments to the company’s compensation policy, and increases in authorized share capital through changes to its articles of association.
For those analyzing WLDS, the filings also reference clinical and technology milestones when they are furnished as exhibits, such as the neurorehabilitation pilot with Soroka University Medical Center and grant support from the Israel Innovation Authority. While detailed financial statements are not included in the excerpts provided here, the 6-K framework allows the company to incorporate press releases and legal opinions by reference into existing registration statements on Form F-3 and Form S-8.
On Stock Titan, users can review these WLDS filings in chronological order and use AI-powered summaries to interpret complex legal and transactional language. The platform highlights essential elements of each report—such as the nature of an offering, key conditions, and referenced exhibits—so readers can more quickly understand how each filing relates to Wearable Devices’ capital structure, governance decisions and product-related disclosures.
Wearable Devices Ltd. is calling a special shareholder meeting on February 19, 2026 to vote on several financing, compensation and capital-structure actions. Shareholders are asked to approve private placements of new warrants, including Ordinary Warrants and amended existing warrants tied to a prior registered direct offering, and a separate inducement grant of New Warrants that could represent 29.1% of fully diluted share capital if exercised. The Board also seeks approval of an amended executive and director compensation policy that raises caps on CEO salary, bonuses and equity awards, plus new RSU grants for the CEO, Chief Scientific Officer/President, and non-executive directors. In addition, shareholders are asked to authorize one or more reverse share splits of up to 3:1 at the Board’s discretion to support continued Nasdaq listing. The Board unanimously recommends voting in favor of all proposals.
Wearable Devices Ltd. has filed an amended prospectus covering the resale of up to 1,670,000 ordinary shares by a single selling shareholder. These shares are issuable from warrants originally sold in September 2025 private placements, with exercise prices currently $4.00 and $6.00 per share that may be reduced to $2.67 per share subject to shareholder approval. The company will receive cash only if the warrants are exercised, which could total about $4.46 million at the reduced price, and plans to use any such proceeds for working capital and general corporate purposes. As of December 16, 2025, 8,648,406 ordinary shares were outstanding, so full exercise of the registered warrants would lift that figure to 10,318,406 shares. The filing also describes additional outstanding warrants, options, RSUs and planned inducement warrants that, if exercised or issued, could substantially increase the share count and dilute existing holders.
Wearable Devices Ltd. reports that it received approval for a $750,000 budget to conduct a neurorehabilitation pilot with Soroka Medical Center. This reflects a funded pilot project focused on neurorehabilitation applications.
The report mainly furnishes a press release about this approval as an exhibit and makes the first two paragraphs and the forward-looking statements section part of several existing Form S-8 and Form F-3 registration statements, so that these disclosures are now formally included in those previously filed share registration documents.
Wearable Devices Ltd. (WLDS) launched a registered direct offering of 655,000 Ordinary Shares and Pre-Funded Warrants to purchase up to 575,000 shares. The Pre-Funded Warrants carry a $0.0001 exercise price and a 9.99% beneficial ownership cap. The combined purchase price is $2.67 per share and $2.6699 per pre-funded unit.
The company estimates net proceeds of approximately $2.9 million for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as financial advisor; the fee table shows $3,284,042 in gross offering price, $262,723 in advisor fees, and $3,021,319 in proceeds before expenses.
In a concurrent private placement (not part of this prospectus), the same investor will receive 1,230,000 unregistered Warrants exercisable at $2.67 per share, effective upon shareholder approval, expiring five years after approval. Ordinary Shares outstanding were 5,960,770 as of October 29, 2025; Ordinary Shares to be outstanding after this offering are 6,615,770.
Wearable Devices Ltd. (WLDS) entered a Securities Purchase Agreement for a registered direct offering to a single institutional investor, selling 655,000 ordinary shares at $2.67 per share and pre‑funded warrants for up to 575,000 shares at $2.6699 each, each with an accompanying ordinary warrant.
The Pre‑Funded Warrants are exercisable immediately at $0.0001 per share and include a 9.99% beneficial ownership cap. In a concurrent private placement, the Company will issue ordinary warrants for up to 1,230,000 shares with a $2.67 exercise price, exercisable upon shareholder approval and expiring five years after approval. The transaction uses an effective Form F‑3 and an October 29, 2025 prospectus supplement.
The Company agreed to 60‑day restrictions on additional issuances and variable‑rate transactions, subject to specified exceptions. Existing September 2025 investor warrants for 1,000,000 shares at $4.00 and 670,000 shares at $6.00 will have their exercise prices reduced to $2.67, subject to shareholder approval, and will expire five years after approval.
Wearable Devices (WLDS) amended its ATM program to $3,864,566 of ordinary shares under its Form F-3 with A.G.P., decreasing the prior $7,400,000 limit. Sales, if any, may be made as “at the market offerings” under Rule 415, with A.G.P. acting on a best efforts basis.
The company has sold $1,256,000 to date under the Sales Agreement. A.G.P. will receive a 3.0% commission on gross sales, and will be deemed an underwriter; indemnification applies as customary. WLDS shares trade on Nasdaq at $2.96 per share as of October 28, 2025. The aggregate market value of ordinary shares held by non‑affiliates was $54,829,754 as of October 29, 2025 under Form F‑3 I.B.5, and the company notes it has sold approximately $9,870,000 of securities in the past 12 months, leaving current I.B.5 capacity of $8,404,757.
Wearable Devices Ltd. (WLDS) filed a Form F-3 preliminary prospectus for the resale of up to 3,322,000 Ordinary Shares by the selling shareholder. These shares are issuable upon exercise of 3,322,000 immediately exercisable New Warrants that expire five years from issuance.
The company will not receive proceeds from any share resales. It may receive up to approximately $5.7 million in cash if the New Warrants are exercised in full for cash at an exercise price of $1.71 per share. As context, shares outstanding were 5,889,873 as of October 24, 2025, and would be 9,211,873 if all New Warrants are exercised for cash. The selling-holder table shows, including Armistice Capital 3,322,000.
The prospectus notes a beneficial ownership limitation of 4.99% (or 9.99% if elected) on certain warrants and highlights potential dilution risks from warrant exercises and future issuances.
Wearable Devices Ltd. (WLDS) reported results of its Annual and Special General Meeting. The meeting on October 24, 2025 was initially adjourned for lack of quorum at 11:00 a.m. (Israel time) but reconvened at 12:00 p.m., where a quorum was present. Shareholders approved Proposal Nos. 1 through 10 by the applicable required majority, as outlined in the September 19, 2025 proxy materials.
Key approvals: an amended and restated Compensation Policy covering new definitions, changes to advance notice and retirement terms, adjustments to grants, inclusion of a non‑compete period, revised special bonus terms, and updated acceleration events for unvested equity awards. Shareholders also approved an increase in authorized share capital by 450,000,000 ordinary shares, bringing total authorized ordinary shares to 500,000,000, and amended the Articles of Association accordingly, effective immediately after approval.
Wearable Devices Ltd. prospectus supplement discloses financing and capitalization details and highlights material risks. The company reported an explanatory paragraph in its interim financial statements expressing substantial doubt about its ability to continue as a going concern. The document lists multiple classes of potentially dilutive securities, including options, warrants, pre-funded warrants, RSUs and reserved shares, with explicit counts such as 3,322,000 Ordinary Shares subject to shareholder approval for warrants, 564,059 RSUs outstanding, 98,589 IPO warrants, and additional warrants exercisable at $4.00 and $6.00 for 1,000,000 and 670,000 shares respectively. A pro forma capitalization table shows total shareholders' equity increasing to $20,104 on a pro forma basis after recent issuances described, and the assumed offering price used for illustrative pro forma calculations is $5.37 per share. The supplement also outlines permitted offering and distribution methods, material terms for warrants and units, and estimated offering expenses including $15,000 legal fees and $3,000 accounting fees.
FAQ
What is the current stock price of Wearable Devices Ltd. (WLDS)?
What is the market cap of Wearable Devices Ltd. (WLDS)?
